Clonazepam During Pregnancy: Not Recommended Unless Absolutely Necessary
Clonazepam should generally be avoided during pregnancy due to documented risks to the fetus and neonate, including potential breathing problems, feeding difficulties, hypothermia, and withdrawal symptoms in newborns. The FDA drug label explicitly states that animal studies have shown harmful effects on the developing fetus, and it is not known if clonazepam can harm an unborn baby 1.
Key Safety Concerns
Neonatal Risks
Children born to mothers receiving benzodiazepines (including clonazepam) late in pregnancy face several documented risks 1:
- Respiratory depression (breathing problems)
- Feeding difficulties
- Hypothermia (temperature regulation problems)
- Neonatal withdrawal syndrome
Pregnancy Complications
Recent high-quality evidence demonstrates that benzodiazepine use during pregnancy is associated with a 69% increased risk of miscarriage (OR 1.69; 95% CI, 1.52-1.87) 2. This 2024 nationwide case-time-control study from Taiwan, involving over 3 million pregnancies, controlled for unmeasured confounders and found consistent results across multiple sensitivity analyses.
Clinical Decision Framework
When Clonazepam Must Be Continued
If a pregnant woman is already taking clonazepam and discontinuation poses greater risks:
Do NOT stop abruptly - Sudden discontinuation can cause status epilepticus (seizures that won't stop) and severe withdrawal 1
Carefully weigh the indication:
- For seizure disorders: The risk-benefit may favor continuation if seizures pose greater maternal/fetal risk
- For panic disorder/anxiety: Alternative non-pharmacologic interventions should be strongly prioritized
Use the lowest effective dose for the shortest duration 3
Divide daily doses into 2-3 administrations to avoid high peak concentrations 3
Avoid first trimester exposure when possible, as this is the critical period for major congenital abnormalities 4
Special Consideration: Concurrent Opioid Use
The 2019 SMFM/ACOG guideline notes that when treating pregnant women with opioid use disorder, methadone may be more appropriate than buprenorphine if there is concurrent benzodiazepine use, due to the risk of central nervous system depression 5. However, the guideline emphasizes that buprenorphine should not be withheld solely due to benzodiazepine co-use; instead, careful medication management is required.
Evidence on Malformations
The teratogenic risk appears relatively low but not definitively established:
- A 2004 surveillance study of 43 first-trimester clonazepam monotherapy exposures found only 1 infant (3%) with major malformations 6
- A 2001 case series of 38 pregnancies showed no orofacial anomalies, neonatal apnea, or withdrawal syndromes, though 2 infants exposed to clonazepam plus imipramine at delivery had transient distress 7
- A 2002 Hungarian case-control study found no detectable teratogenic risk, though data were limited 4
Critical caveat: These studies had small sample sizes and insufficient power to definitively rule out increased malformation risk 6.
Practical Management
If Pregnancy is Discovered While on Clonazepam:
- Immediately consult with the prescribing physician - do not self-discontinue
- Register with the North American Antiepileptic Drug Pregnancy Registry (1-888-233-2334) 1
- Implement slow taper if discontinuation is appropriate, with close monitoring for withdrawal symptoms
- Arrange enhanced prenatal monitoring for fetal growth and neonatal complications
Neonatal Monitoring at Delivery:
Infants exposed to clonazepam late in pregnancy require close observation for:
- Respiratory depression
- Feeding difficulties
- Temperature instability
- Withdrawal symptoms (irritability, tremors, poor feeding)
Breastfeeding Consideration:
Clonazepam passes into breast milk 1. The decision to breastfeed should involve careful discussion with the healthcare provider weighing maternal mental health needs against neonatal exposure risks.
Bottom Line Algorithm
Is the indication life-threatening or severely disabling?
- No (e.g., mild anxiety, insomnia) → Discontinue with slow taper; use non-pharmacologic alternatives
- Yes (e.g., severe seizure disorder, debilitating panic disorder unresponsive to alternatives) → Continue at lowest effective dose with enhanced monitoring
The default position should be avoidance, given the documented 69% increased miscarriage risk 2 and neonatal complications 1, unless the maternal condition poses equal or greater risk to pregnancy outcomes.